BR112013021661A2 - objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas - Google Patents
objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadasInfo
- Publication number
- BR112013021661A2 BR112013021661A2 BR112013021661A BR112013021661A BR112013021661A2 BR 112013021661 A2 BR112013021661 A2 BR 112013021661A2 BR 112013021661 A BR112013021661 A BR 112013021661A BR 112013021661 A BR112013021661 A BR 112013021661A BR 112013021661 A2 BR112013021661 A2 BR 112013021661A2
- Authority
- BR
- Brazil
- Prior art keywords
- objectification
- tlt
- coagulation factor
- activated platelets
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Abstract
patente de invenção: "objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas. a presente invenção refere-se às proteínas pró-coagulantes que podem, por exemplo, ser proteínas de fusão ou conjugados químicos, métodos de produção das referidas proteínas pró-coagulantes, polinucleotídeos que codificam as referidas proteínas de fusão e células que expressam as mesmas. além disso, a presente invenção refere-se às proteínas pró-coagulantes para uso como um medicamento. indivíduos que têm uma coagulopatia tal como, por exemplo, hemofilia a e b, com ou sem inibidores, podem ser tratados com as proteínas pró-coagulantes da presente invenção.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11156682 | 2011-03-02 | ||
US201161449254P | 2011-03-04 | 2011-03-04 | |
PCT/EP2012/053619 WO2012117091A1 (en) | 2011-03-02 | 2012-03-02 | Coagulation factor-targeting to tlt-1 on activated platelets |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013021661A2 true BR112013021661A2 (pt) | 2016-11-22 |
Family
ID=44558650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013021661A BR112013021661A2 (pt) | 2011-03-02 | 2012-03-02 | objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas |
Country Status (13)
Country | Link |
---|---|
US (3) | US20130337537A1 (pt) |
EP (1) | EP2680875B1 (pt) |
JP (2) | JP6309273B2 (pt) |
KR (1) | KR20140012082A (pt) |
CN (1) | CN103429256B (pt) |
AU (1) | AU2012222366A1 (pt) |
BR (1) | BR112013021661A2 (pt) |
CA (1) | CA2828769A1 (pt) |
IL (1) | IL227501A0 (pt) |
MX (1) | MX2013009862A (pt) |
RU (1) | RU2013142015A (pt) |
WO (1) | WO2012117091A1 (pt) |
ZA (1) | ZA201306111B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
EA201291482A1 (ru) | 2010-07-09 | 2013-10-30 | Байоджен Айдек Хемофилия Инк. | Химерные факторы коагуляции |
KR102349370B1 (ko) * | 2014-05-26 | 2022-01-10 | 삼성전자주식회사 | 인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도 |
US11685785B2 (en) * | 2015-06-12 | 2023-06-27 | Ascendo Biotechnology, Inc. | Methods and antibodies for modulation of immunoresponse |
CA3034105A1 (en) | 2016-09-23 | 2018-03-29 | Csl Limited | Coagulation factor binding proteins and uses thereof |
RU2019118427A (ru) | 2016-11-16 | 2020-12-17 | БАЙЕР ХелсКер ЛЛСи | Нацеленный на эритроциты фактор viii и способ его применения |
EP3454063B1 (de) * | 2017-09-06 | 2022-05-18 | AVA Lifescience GmbH | Durchflusszytometrie-messverfahren |
US10597462B1 (en) * | 2017-11-08 | 2020-03-24 | University Of Puerto Rico | Anti-TLT-1 antibody and uses thereof |
JP7297928B2 (ja) | 2019-04-17 | 2023-06-26 | ノヴォ ノルディスク アー/エス | 二重特異性抗体 |
WO2020226907A1 (en) * | 2019-05-07 | 2020-11-12 | Beijing Neoletix Biological Technology Co., Ltd. | Fusion protein of single domain antibody and procoagulant |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
CA2053317C (en) | 1989-04-19 | 1996-03-12 | Shmuel Zalipsky | Active carbonates of polyalkylene oxides for modification of polypeptides |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
JP4451514B2 (ja) | 1999-08-24 | 2010-04-14 | 財団法人化学及血清療法研究所 | 血液凝固第vii因子改変体 |
JP4455802B2 (ja) | 2000-05-03 | 2010-04-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト第vii凝固因子変異型 |
AU2001287550B2 (en) | 2000-09-13 | 2007-03-22 | Novo Nordisk Health Care Ag | Human coagulation factor VII variants |
AU2002218029A1 (en) | 2000-11-09 | 2002-05-21 | The Scripps Research Institute | Modified factor viia |
HUP0401124A3 (en) | 2001-03-22 | 2006-01-30 | Novo Nordisk Healthcare Ag | Coagulation factor vii derivatives |
CA2461003A1 (en) | 2001-09-27 | 2003-04-03 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
PT2279753E (pt) | 2001-10-10 | 2016-01-15 | Novo Nordisk As | Remodelação e glicoconjugação de péptidos |
EP1451315B1 (en) | 2001-11-02 | 2014-05-21 | Novo Nordisk Health Care AG | Human coagulation factor vii polypeptides |
EP1546202B1 (en) | 2002-09-25 | 2007-08-22 | Novo Nordisk Health Care AG | Human coagulation factor vii polypeptides |
US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US20040180409A1 (en) * | 2003-03-16 | 2004-09-16 | Mcvicar Daniel | TLT-1, a novel platelet-associated receptor and uses therefor |
CA2522345A1 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
PT2298347E (pt) * | 2003-05-06 | 2016-01-29 | Biogen Hemophilia Inc | Proteínas quiméricas de fator de coagulação para o tratamento de um disturbio hemostático |
JP2006527590A (ja) | 2003-06-18 | 2006-12-07 | ディレボ・ビオテク・アーゲー | 新規生物学的実体およびその使用 |
EP1664291B1 (en) | 2003-09-09 | 2012-02-29 | Novo Nordisk Health Care AG | Coagulation factor vii polypeptides |
US7393833B2 (en) | 2005-03-09 | 2008-07-01 | The Board Of Regents Of The University Of Oklahoma | Chimeric proteins with phosphatidylserine binding domains |
JP2008543297A (ja) | 2005-06-15 | 2008-12-04 | ノボ ノルディスク ヘルス ケア アーゲー | トランスグルタミナーゼを介した成長ホルモンのコンジュゲート |
EP1926817A2 (en) | 2005-09-14 | 2008-06-04 | Novo Nordisk Health Care AG | Human coagulation factor vii polypeptides |
CN101389356B (zh) | 2006-01-06 | 2012-09-05 | 武冈真司 | 药物输送物质 |
JP5216219B2 (ja) * | 2006-01-06 | 2013-06-19 | 真司 武岡 | 薬物運搬体 |
US7553936B2 (en) * | 2006-12-04 | 2009-06-30 | The United States of America as represented by Secretary Department of Health and Human Services | Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions |
EP2162472B1 (en) | 2007-05-30 | 2013-02-27 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
AU2009219232B2 (en) | 2008-02-27 | 2014-02-27 | Novo Nordisk A/S | Conjugated Factor VIII molecules |
WO2009140598A1 (en) * | 2008-05-16 | 2009-11-19 | Bayer Healthcare Llc | Targeted coagulation factors and method of using the same |
EP2149603A1 (en) | 2008-07-28 | 2010-02-03 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders |
JP5977945B2 (ja) | 2008-08-06 | 2016-08-24 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 長期のインビボ有効性を有するコンジュゲートタンパク質 |
EP2417155B1 (en) * | 2009-04-06 | 2013-06-19 | Novo Nordisk A/S | Targeted delivery of factor viii proteins to platelets |
ES2898683T3 (es) * | 2009-08-27 | 2022-03-08 | Novo Nordisk As | Direccionamiento del factor tisular a las plaquetas activadas |
-
2012
- 2012-03-02 RU RU2013142015/10A patent/RU2013142015A/ru unknown
- 2012-03-02 MX MX2013009862A patent/MX2013009862A/es unknown
- 2012-03-02 BR BR112013021661A patent/BR112013021661A2/pt not_active Application Discontinuation
- 2012-03-02 US US13/982,360 patent/US20130337537A1/en not_active Abandoned
- 2012-03-02 EP EP12707095.1A patent/EP2680875B1/en active Active
- 2012-03-02 KR KR1020137023069A patent/KR20140012082A/ko not_active Application Discontinuation
- 2012-03-02 CA CA2828769A patent/CA2828769A1/en not_active Withdrawn
- 2012-03-02 WO PCT/EP2012/053619 patent/WO2012117091A1/en active Application Filing
- 2012-03-02 JP JP2013555888A patent/JP6309273B2/ja active Active
- 2012-03-02 CN CN201280011375.7A patent/CN103429256B/zh active Active
- 2012-03-02 AU AU2012222366A patent/AU2012222366A1/en not_active Withdrawn
-
2013
- 2013-07-16 IL IL227501A patent/IL227501A0/en unknown
- 2013-08-14 ZA ZA2013/06111A patent/ZA201306111B/en unknown
-
2016
- 2016-04-08 US US15/094,082 patent/US20160263230A1/en not_active Abandoned
-
2017
- 2017-12-07 JP JP2017235148A patent/JP2018043997A/ja active Pending
-
2018
- 2018-09-07 US US16/125,026 patent/US11135275B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2012222366A1 (en) | 2013-08-01 |
IL227501A0 (en) | 2013-09-30 |
JP2014509326A (ja) | 2014-04-17 |
JP2018043997A (ja) | 2018-03-22 |
EP2680875B1 (en) | 2019-10-23 |
KR20140012082A (ko) | 2014-01-29 |
ZA201306111B (en) | 2014-04-30 |
MX2013009862A (es) | 2013-10-25 |
US20160263230A1 (en) | 2016-09-15 |
JP6309273B2 (ja) | 2018-04-11 |
RU2013142015A (ru) | 2015-04-10 |
CN103429256A (zh) | 2013-12-04 |
WO2012117091A1 (en) | 2012-09-07 |
US20130337537A1 (en) | 2013-12-19 |
CA2828769A1 (en) | 2012-09-07 |
US20190083587A1 (en) | 2019-03-21 |
EP2680875A1 (en) | 2014-01-08 |
US11135275B2 (en) | 2021-10-05 |
CN103429256B (zh) | 2022-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013021661A2 (pt) | objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas | |
BR112014000466A2 (pt) | polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos | |
MX2018011836A (es) | Conjugados de anticuerpo farmaco anti-cd70. | |
CL2017002082A1 (es) | Nuevas proteínas especificas para pioverdina y pioquelina | |
WO2014062733A3 (en) | Substituted benzene compounds | |
BR112016022553A2 (pt) | Compostos e métodos para entrega transmembrana de moléculas? | |
BR112012017488A2 (pt) | "dispositivo" | |
BR112015015898A8 (pt) | composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
UA110470C2 (ru) | Антидот антикоагулянта | |
EA201590910A1 (ru) | Белки на основе структурного домена фибронектина, связывающие pcsk9 | |
WO2014076321A8 (en) | Novel specific-binding polypeptides and uses thereof | |
BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
BR112015015864A2 (pt) | composição farmacêutica, método de preparação de uma composição farmacêutica, método de tratamento de um indivíduo com uma condição de dor severa, e, uso de uma composição farmacêutica | |
CO7111276A2 (es) | Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met | |
BR112015022139A2 (pt) | uso de poliésteres com proteção inerente às chamas em adesivos e materiais de vedação | |
BR112015013349A2 (pt) | trieptanoína para o tratamento de deficiência de transportador de glicose 1 | |
WO2014140103A3 (en) | Thrombin sensitive coagulation factor x molecules | |
BR112014031841A2 (pt) | formulação farmacêutica | |
BR112013000779A2 (pt) | composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial | |
UY33219A (es) | Cetoenoles cíclicos para terapias | |
BR112014011481A2 (pt) | hidrolisado de colágeno e seu uso | |
BR112015013071A2 (pt) | solução de trombina e seus métodos de uso | |
BR112014027213A2 (pt) | nova composição de alfentanil para o tratamento da dor aguda | |
BR112015024877A2 (pt) | vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose | |
BR112015017546A2 (pt) | composições hemostáticas, usos das mesmas e kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |